On July 24, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,360,499, a key component of Anixa’s Cchek technology for early detection of cancer (Press release, Anixa Biosciences, JUL 24, 2019, View Source [SID1234537699]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This patent provides broader coverage for the use of Anixa’s technology in a wider range of applications and protects critical new improvements developed for Anixa’s cancer detection technology, utilizing flow cytometry and artificial intelligence.

"The claims of this patent were allowed in March of this year as noted in a previous announcement, and we are pleased that this key patent has finally been issued," stated Dr. Amit Kumar, President and CEO of Anixa. "We are pleased to receive further patent protection on our liquid biopsy technology and look forward to launching a prostate cancer confirmatory test as the first product utilizing this technology later this year."

The patent is titled, "METHODS FOR USING ARTIFICIAL NEURAL NETWORK ANALYSIS ON FLOW CYTOMETRY DATA FOR CANCER DIAGNOSIS." Inventors of the patent include Dr. Amit Kumar, John Roop, Anthony Campisi, and Dr. George Dominguez. This patent is held exclusively by Anixa and is not licensed to any third parties.